Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M.D. Crew, R.B. Effros, R.L. Walford, E. Zeller, H. Cheroutre, E. Brahn.
Transgenic mice expressing a truncated Peromyscus leucopus TNF-alpha gene manifest an arthritis resembling ankylosing spondylitis.
J Interferon Cytokine Res, 18 (1998), pp. 219-225
[2.]
J. Gratacós, A. Collado, X. Filella, R. Sanmartí, J. Canete, J. Llena, et al.
Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity.
Br J Rheumatol, 33 (1994), pp. 927-931
[3.]
D. Baeten, E. Kruithof, F. Van den Bosch, P. Demetter, N. Van Damme, C. Cuvelier, et al.
Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study.
Arthritis Rheum, 44 (2001), pp. 186-195
[4.]
J.D. Canete, J. Llena, A. Collado, R. Sanmartí, A. Gaya, J. Gratacós, et al.
Comparative cytokine gene expression in synovial tissue of early rheumatoid arthritis and seronegative spondyloarthropathies.
Br J Rheumatol, 36 (1997), pp. 38-42
[5.]
P. Ettehadi, M.W. Greaves, D. Wallach, D. Aderka, R.D. Camp.
Elevated tumor necrosis factor alpha biological activity in psoriatic skin lesions.
Clin Exp Immunol, 96 (1994), pp. 146-151
[6.]
P. Mease, D.D. Gladman, C.T. Ritchlin, E.M. Ruderman, S.D. Steinfeld, E.H.S. Coy.
Adalimumab therapy in patients with psoriatic arthritis: 24-week. Results of a Phase III Study ADEPT-Adalimumab effectiveness in psoriatic arthritis.
Arthritis Rheum, 509 (2004), pp. 4096-4097
[7.]
B. Menter, K.B. Gordon, M. Leonardi, M.P. Hefferman, D.M. Chen.
Adalimumab is effective in treating moderate to severe plaque psoriasis in patients with and without PsA. Adalimumab is well-tolerated in this patient population.
Arthritis Rheum, 509 (2004), pp. S815-S816
[8.]
Haibel H, Rudwaleit M, Brandt H, Grozdanovic Z, Braun J, Kupper H, et al. Preliminary MRI results in patients with active ankylosing spondylitis treated with adalimumab for 12 weeks. Arthritis Rheum. 2004:509 Suppl pS618 [abstract 1.640]. Presentation number: 1.640, Poster Board Number: 462.
[9.]
Haibel H, Brandt H, Rudwaleit M, Listiny J, Braun J, Kupper H, et al. Effycacy and safety of adalimumab in the treatmentof active ankylosing spondylitis: preliminary results of ad open-label 20.week trial. Arthritis Rheum. 2004; 509 Suppl pS217 [abstract 454]. Presentation number: 454, Poster Board Number: 458.
Copyright © 2005. Elsevier España S.L. Barcelona
